CRL vs WLYB · rev $2.00B vs P/E 15, rev $1.68B
Charles River Laboratories (CRL) versus John Wiley & Sons B (WLYB) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
John Wiley & Sons B (WLYB) is a publishing company listed on NYSE.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported WLYB revenue for 2026-04-30 was $1.68B. Net income was $221.6M. Revenue was down 0.1% from 2025-04-30 to 2026-04-30. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
CRL currently screens at market cap $7.78B. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
Not investment advice. Open the CRL and WLYB stock pages for the full models.
Not investment advice.